Colonic Diseases, Functional Clinical Trial
Official title:
Clinical Study to Test the Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With IBS
To test the efficacy of herbal medicine in relieving symptoms and change of quality of life of patients with IBS.
Irritable bowel syndrome (IBS) is a diagnosis in Western Medicine characterized by recurrent abdominal pain associated with disturbance in bowel habit such as diarrhea or constipation. Epidemiological studies showed that 14% of males and 27% of females in the US (white) have symptoms of IBS. In Hong Kong, our survey reported a similar prevalence of this condition among Chinese (13% in males and 21% in females). IBS is one of the most common conditions leading to seeking of medical care. Treatment for IBS has so far been unsatisfactory. Numerous medications have been proposed for IBS; however, none is convincingly effective. A review and critique of published drug trials for IBS from 1966 to 1988 concluded that there was no proof that any western medicine is effective for all IBS patients. With the unsatisfactory treatment response of western medicine, many turned to alternative treatment modalities for IBS. Traditional Chinese medicine is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions has been known for centuries. However, there is a lack of convincing clinical data demonstrating the effectiveness of Chinese medicine in this condition. In this study, we sought to determine the efficacy of herbal medicine in relieving symptoms and quality of life of patients with IBS. This is a prospective randomized, double-blinded double placebo-controlled study in patients with non-constipation type IBS. Patients will be randomized to receive either one of three treatment arms: 1. herbal medicine (HM) + placebo western medicine (WM), 2. WM + placebo HM and 3. placebo HM + placebo WH. Each patient will go through an 8-week period of randomized double-blind treatment with either HW, WM or placebo and followed by an 8-week of observation period. The IBS symptom and quality of life will be compared. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT03922815 -
Adequacy of Anaesthesia for Colonoscopic Procedures
|
N/A | |
| Not yet recruiting |
NCT06271538 -
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
|
Phase 4 | |
| Completed |
NCT01176227 -
Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)
|
Phase 1/Phase 2 | |
| Completed |
NCT01887834 -
Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT00130741 -
Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)
|
Phase 1 | |
| Completed |
NCT01072903 -
The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)
|
N/A | |
| Active, not recruiting |
NCT01028898 -
Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT03854422 -
For Easy, Fast and Comfortable Colonoscopy, Which Position
|
N/A | |
| Completed |
NCT02551029 -
fMRI and Visceral Perception Upon Capsaicin Infusion
|
N/A | |
| Completed |
NCT02716285 -
Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery
|
Phase 3 | |
| Completed |
NCT05340400 -
The Prevalence and Risk Factors of Irritable Bowel Syndrome Among Adults
|
||
| Completed |
NCT00189033 -
Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?
|
N/A |